Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics


Fulcrum Therapeutics, Inc. (FULC): $8.36

0.02 (+0.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FULC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FULC POWR Grades


  • FULC scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.15% of US stocks.
  • FULC's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • FULC's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

FULC Stock Summary

  • The ratio of debt to operating expenses for Fulcrum Therapeutics Inc is higher than it is for about merely 0.5% of US stocks.
  • With a price/sales ratio of 45.61, Fulcrum Therapeutics Inc has a higher such ratio than 95.88% of stocks in our set.
  • As for revenue growth, note that FULC's revenue has grown 117.19% over the past 12 months; that beats the revenue growth of 93.01% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Fulcrum Therapeutics Inc, a group of peers worth examining would be CGEN, SURF, PRQR, CDAK, and FUSN.
  • Visit FULC's SEC page to see the company's official filings. To visit the company's web site, go to www.fulcrumtx.com.

FULC Valuation Summary

  • In comparison to the median Healthcare stock, FULC's price/earnings ratio is 136.16% lower, now standing at -13.2.
  • FULC's EV/EBIT ratio has moved down 5.1 over the prior 26 months.
  • FULC's price/earnings ratio has moved down 5.2 over the prior 26 months.

Below are key valuation metrics over time for FULC.

Stock Date P/S P/B P/E EV/EBIT
FULC 2021-08-31 63.7 8.8 -13.2 -12.5
FULC 2021-08-30 59.0 8.1 -12.3 -11.5
FULC 2021-08-27 58.2 8.0 -12.1 -11.3
FULC 2021-08-26 56.7 7.8 -11.8 -11.0
FULC 2021-08-25 58.3 8.0 -12.1 -11.3
FULC 2021-08-24 56.4 7.8 -11.7 -10.9

FULC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FULC has a Quality Grade of D, ranking ahead of 14.4% of graded US stocks.
  • FULC's asset turnover comes in at 0.108 -- ranking 260th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows FULC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.108 1 -1.792
2021-03-31 0.090 1 -1.731
2020-12-31 0.069 1 -1.552
2020-09-30 0.037 1 -2.003
2020-06-30 0.024 1 -2.355
2020-03-31 0.008 1 -3.830

FULC Price Target

For more insight on analysts targets of FULC, see our FULC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.86 Average Broker Recommendation 1.5 (Moderate Buy)

FULC Stock Price Chart Interactive Chart >

Price chart for FULC

FULC Price/Volume Stats

Current price $8.36 52-week high $33.10
Prev. close $8.34 52-week low $6.85
Day low $7.97 Volume 739,624
Day high $8.55 Avg. volume 601,916
50-day MA $14.12 Dividend yield N/A
200-day MA $17.88 Market Cap 341.49M

Fulcrum Therapeutics, Inc. (FULC) Company Bio


Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.


FULC Latest News Stream


Event/Time News Detail
Loading, please wait...

FULC Latest Social Stream


Loading social stream, please wait...

View Full FULC Social Stream

Latest FULC News From Around the Web

Below are the latest news stories about Fulcrum Therapeutics Inc that investors may wish to consider to help them evaluate FULC as an investment opportunity.

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2021 financial results will be released on Thursday, March 3, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on rec

Yahoo | February 24, 2022

These 2 Stocks Could Be Bought Out, Says Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth a total of $2.5 trillion, more than 25% higher than the previous record, 2015’s $1.96 trillion.

Michael Marcus on TipRanks | February 15, 2022

2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth

Yahoo | February 15, 2022

Multiple insiders bought Fulcrum Therapeutics, Inc. (NASDAQ:FULC) stock earlier this year, a positive sign for shareholders

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | February 12, 2022

Read More 'FULC' Stories Here

FULC Price Returns

1-mo -23.86%
3-mo -16.06%
6-mo N/A
1-year -9.82%
3-year N/A
5-year N/A
YTD -52.74%
2021 51.07%
2020 -29.63%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7982 seconds.